In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva buys Teva Marion interest from Aventis

Executive Summary

Israeli generics company Teva Pharmaceutical will acquire the remaining interest of Teva Marion Partners from Aventis. The 50/50 joint venture was originally set up in 1995 by Hoechst's Marion Merrell Dow division--before the merger of Hoechst and Rhone-Poulenc created Aventis--to market the injectable multiple sclerosis drug Copaxone (glatiramer acetate).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout

Related Companies